drugset
drugset / Trial / NCT02352025

S-equol in Women With Triple Negative Breast Cancer

NCT02352025 ↗

Phase 0 Completed 39 enrolled The University of Texas Health Science Center at San Antonio
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to determine if S-equol, an ER-beta agonist, is effective in decreasing the proliferation rate of triple negative breast cancer.

Timeline

Start
2015-04-15
Primary completion
2019-04-10
Completion
2020-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject AUS-131 Small molecule 50 mg Oral

Indications

breast cancer